New Jersey federal judge Freda Wolfson rejected Mylan‘s (NSDQ:MYL) request to move an antitrust lawsuit brought against the EpiPen maker to Kansas. Mylan previously claimed that moving the case to Kansas would consolidate it with other class actions from EpiPen buyers – all of which are alleging violations of antitrust laws. Wolfson blocked the request […]
Drug-Device Combinations
Sunovion divests asthma, allergy tech to Covis Pharma
Sunovion Pharmaceuticals said today that it plans to divest the U.S. market rights for its allergy and asthma products to Covis Pharma, in an effort to narrow its focus to the company’s COPD portfolio. Included in the deal is Sunovion’s Alvesco inhalation aerosol, its Omnaris nasal spray and its Zetonna nasal aerosol. All three products […]
Bigfoot Biomedical taps Abbott to collaborate on automated insulin delivery tech
Abbott (NYSE:ABT) and Bigfoot Biomedical said today that the companies inked a deal to develop and commercialize diabetes management systems. The collaboration will bring together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin delivery platform, the companies reported. According to the deal, Abbott will provide Bigfoot with the next-gen version of its FreeStyle Libre continuous […]
Milestone Scientific appoints new CEO following FDA nod | Personnel Moves – July 13, 2017
Milestone Scientific (NYSE:MLSS) said this week that it appointed Daniel Goldberger to the company’s corner office. Leonard Osser, who previously served as CEO, is slated to remain on the board and will continue to serve as director of Milestone’s China operations. The appointment comes on the heels of the FDA’s decision to grant Milestone’s CompuFlo epidural […]
Study: Nanomedicine shuts down cells that drive cancer growth in glioblastoma
Researchers from Northwestern Medicine have developed lipid polymer-based nanoparticles that target key cancer drivers, called brain tumor initiating cells, in a mouse model of glioblastoma brain tumors. “BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, […]
Synspira’s therapy could boost antibiotics against drug-resistant bacteria in CF patients
Privately-held Synspira touted a study today of its inhaled glycopolymer-based therapeutic with antibiotics as a potential treatment for pulmonary infection caused by the Burkholderia cepacia complex in patients with cystic fibrosis. The study was published in PLOS One. Synspira’s lead polycationic glycopolymer, SNSP113, was studied in combination with tobramycin and meropenem. These antibiotics, as well as ceftazidime, are often […]
BioDelivery Sciences, Purdue ink exclusive distribution deal for Belbuca in Canada
BioDelivery Sciences International (NSDQ:BDSI) said today that it inked an exclusive distribution deal with Purdue Pharma‘s Canada branch for the licensing, distribution, marketing and sale of Belbuca in Canada. The company’s Belbuca buccal film was designed to deliver buprenorphine for patients with chronic pain. It was cleared by Health Canada in June for patients with pain severe […]
First cell and gene therapy for osteoarthritis approved in Korea
Maryland-based TissueGene said today that Invossa, which it touts as the world’s first cell and gene therapy for degenerative arthritis, won approval from the Korea Ministry of Food and Drug Safety. Invossa is designed to treat osteoarthritis of the knee through a single intra-articular injection. Kolon Life Science (KSDQ:102940), TissueGene’s exclusive licensee for Asia, filed for a […]
FDA rejects Ocular’s Dextenza for a second time
Ocular Therapeutix (NSDQ:OCUL) said today that the FDA rejected its resubmission of a new drug application for Dextenza. This is the second time that Ocular has received the FDA’s dreaded complete response letter for Dextenza. In July last year, the FDA denied approval for Ocular’s hydrogel plug after it discovered ‘deficiencies in manufacturing process and controls’ in a pre-new […]
Equashield seeks to automate hazardous drug handling: a Drug Delivery Business News podcast
Equashield’s Jason Dutcher chats with Drug Delivery Business News editor Sarah Faulkner about the company’s closed system transfer device and its latest move to automate hazardous drug compounding. Healthcare workers are often tasked with handling hazardous drugs, which give off harmful vapors. Exposure to these drugs has been linked to severe health risks, including infertility, […]
